Roche Holding AG





Market Closed - Swiss Exchange 11:31:22 2024-04-12 am EDT 5-day change 1st Jan Change
225 CHF -0.49% Intraday chart for Roche Holding AG +2.51% -7.98%
This Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating ZD
Swiss Market Index Falls as ECB Signals June Rate Cut MT
ROCHE HOLDINGS AG : Berenberg reiterates its Neutral rating ZD
Roche: designation for Alzheimer's test CF
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review DJ
Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation MT
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis CI
Swiss Market Index Little Changed; Barry Callebaut Shines on Revenue Jump MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark MT
Roche: CE mark for Enhertu companion test CF
Novartis to cut 680 jobs in product development RE
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating ZD
ROCHE HOLDINGS AG : Barclays gives a Neutral rating ZD
Roche: positive phase II data in hypertension CF
Roche's Hypertension Drug Meets Primary Endpoint of Reduced Systolic Blood Pressure in Mid-stage Trial MT
ROCHE HOLDINGS AG : Receives a Sell rating from JP Morgan ZD
ROCHE HOLDINGS AG : Gets a Sell rating from JP Morgan ZD
Global markets live: Apple, UBS, Microstrategy, Merck, Amazon... Our Logo
Roche's Chugai Wins Japanese Approval for Piasky Injection MT
Roche Obtains US FDA Approval for Cobas Malaria Test MT
Roche Gets FDA Approval for Malaria Screen Test DJ
Roche: FDA green light for 'cobas' test CF
Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors CI
ROCHE HOLDINGS AG : Deutsche Bank reiterates its Sell rating ZD
ROCHE HOLDINGS AG : Gets a Sell rating from Deutsche Bank ZD
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
225 CHF
Average target price
281.3 CHF
Spread / Average Target
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Holding : Q4 miss weighed heavily on the healthy 2024 guidance